Furthermore, studies have demonstrated a correlation between IDH2 and the tumor microenvironment (TME) in patients with nTFHL-AI (7, 30), suggesting a role for epigenetic mutations in the variation of clinicopathological features. The gene discussed is IDH2; the disease is neoplasm.